Cambridge, MA-based regenerative medicine firm Pervasis Therapeutics has raised $9.75 million in new funding from Flagship Venture Partners, Polaris Venture Partners, Highland Capital Partners, and Musket Research Associates, the firm announced today. Pervasis will use the funds to further the development of Vascugel, a blood-vessel-repair product, as well as research into other applications of its technology.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
